Hepatic veno-occlusive disease (VOD) is a major complication after hematopoietic stem cell transplantation (HSCT). Aetiological determinants, diagnosis and treatment remain unclear. Changes in coagulationfibrinolysis parameters and N-terminal propeptide for type III procollagen (P-III-P) have been studied in patients with or without VOD after HSCT. We prospectively measured protein C activity, tissue plasminogen activator (t-PA), antithrombin III (AT-III), plasminogen activity (PLG), thrombin-antithrombin III (TAT), ␣2-plasmin inhibitor (␣2-PI),fibrinogen (Fbg) and P-III-P in 44 consecutive adult patients undergoing allogeneic HSCT. Each parameter was determined before conditioning, on day 0 of HSCT and weekly for 5 weeks. Five of the 44 patients developed VOD at a median post HSCT of day 3 (range, day 3 to 12). On repeated analysis of variance (ANOVA), there were significant differences between patients with and without VOD in P-III-P (P Ͻ 0.0001), protein C (P Ͻ 0.0001), t-PA (P Ͻ 0.0001), PLG (P Ͻ 0.0001), AT-III(P Ͻ 0.0001), Fbg (P Ͻ 0.0001), ␣2-PI (P = 0.0002). Levels of P-III-P were significantly higher in patients with VOD than without VOD, before preparative chemotherapy (P Ͻ 0.005) and on days 0 and 7 (P Ͻ 0.001). On day 0, levels of t-PA were significantly higher in patients with VOD than without VOD (P Ͻ 0.05). On day 7, levels of protein C were significantly lower in patients with VOD than without VOD (P Ͻ 0.01). On day 0, there were trends of differences (P = 0.0515) between patients with and without VOD in the levels of protein C. These results suggest P-III-P, t-PA and protein C are predictive markers for VOD after HSCT in adults. Moreover, the serum P-III-P level before start of conditioning might indicate patients at risk for developing VOD. Bone Marrow Transplantation (2000) 26, 881-886.
Hepatic veno-occlusive disease (VOD) is one of the serious complications of hematopoietic stem cell transplantation (HSCT) characterized by painful hepatomegaly, ascites and jaundice. 1 Its frequency varies greatly from 1 to 54%, 2, 3 and mortality rate is high. VOD may possibly arise from injury or disruption of the endothelium lining the sinusoids and pores connected to the hepatic venular lumen. Endothelial injury causes activation of the coagulation system and post-sinusoidal obstruction, but the pathogenesis is not clear and the diagnosis of VOD is based only on clinical criteria advocated by the Seattle or Baltimore groups. 1, 4, 5 Thus, changes in hemostatic parameters have been examined after HSCT. Decreases in natural anticoagulants such as protein C 6 and antithrombin III (ATIII) 7 have been observed after HSCT. Increases in the serum concentration of the N-terminal propeptide for type III procollagen (P-III-P), which has been found to be a sensitive marker for pulmonary and liver fibrosis, have been observed after HSCT. 8, 9 However, there are few papers in which both coagulation-fibrinolysis markers and P-III-P were prospectively measured after HSCT.
In this study, we prospectively measured the level of coagulation-fibrinolysis markers and P-III-P in 44 consecutive patients undergoing allogeneic HSCT; furthermore, we determined whether we could find an early predictive marker for the development of VOD among these measurements.
Patients and methods

Patients
All patients more than 15 years of age who underwent allogeneic hematopoietic stem cell transplantation in Tokyo Metropolitan Komagome Hospital from January 1998 to March 1999 were enrolled into the study. Written informed consent was obtained from all patients. Forty-two of 44 enrolled patients underwent first bone marrow transplantation. One patient with severe aplastic anemia suffering from late graft failure after BMT underwent allogeneic peripheral blood stem cell transplantation. Only one patient with acute lymphoblastic leukemia (ALL) in second complete remission underwent a second BMT. This patient was transplanted from an HLA-A one-locus-mismatched sister.
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The following preparation regimens were used. Patients with myeloid malignancies who underwent related BMT received busulfan (4 mg/kg) for 4 days and cyclophosphamide (CY) (60 mg/kg) for 2 days (BU + CY). Patients with myeloid malignancies who underwent unrelated BMT received BU + CY followed by total lymphoid irradiation (TLI), 7 Gy in two fractions. Patients with lymphoid malignancies who underwent first BMT received four doses of 2 g/m 2 cytosine arabinoside over 3 days, 60 mg/kg of CY for 2 days and 12 Gy of total body irradiation (TBI) in six fractions over a period of 3 days. One patient who underwent second BMT received BU + CY. One patient with severe aplastic anemia who underwent allogeneic second hematopoietic stem cell transplantation received rabbit antithymocyte globulin (ATG) (2 mg/kg/day × 4 days) followed by TBI (2 Gy × 2/day × 2 days). All patients received short-term methotrexate and cyclosporine for GVHD prophylaxis. No patients received any prophylaxis for VOD, which could have affected the coagulation profile.
Diagnosis of hepatic VOD
All enrolled patients were monitored prospectively for VOD. A diagnosis of VOD was made according to the clinical criteria 3 of two of the following being present before day 20 post transplant: (1) hyperbilirubinemia (bilirubin у 2.0 mg/dl or 34.2 mol/l), (2) painful hepatomegaly, and (3) unexplained weight gain (Ͼ2% from baseline), no other explanation for these signs and symptoms being present at the time of diagnosis. Severity of VOD was classified into mild, moderate, or severe. 3 Patients who met the criteria for VOD, but who were not treated and whose illness was self-limited, were considered to have mild VOD. Those whose VOD resolved but who received treatment such as diuretics for fluid retention or narcotic analgesics for painful hepatomegaly, were considered to have moderate VOD. Patients were classified as having severe VOD if they experienced adverse effects from liver disease, and signs, symptoms, and laboratory values did not resolve before day 100 or the patient died, whichever occurred first.
Assays of coagulation-fibrinolysis parameters
Protein C activity, tissue plasminogen activator (t-PA), antithrombin III (AT-III), plasminogen activity (PLG), thrombin-antithrombin III (TAT), ␣2-plasmin inhibitor (␣2-PI),fibrinogen (Fbg) were monitored in all enrolled patients. Each coagulation-fibrinolysis parameter was determined before preparative chemotherapy, on the day of marrow or peripheral blood stem cell infusion (day 0), and on days 7, 14, 21, 28 and 35. Venous blood was collected in 1/10th volume of 3.8% sodium citrate. Plasma samples were separated by centrifugation at 2000 g for 10 min, 4°C and stored at −80°until assayed. Protein C activity was determined by a Behring fibrin timer A coagulometer with a commercial kit (protein C clot BW; Behringwerke, Marburg, Germany). The t-PA and TAT were measured by enzyme immunoassay (EIA) with commercial kits (t-PA: Imulyse tPA; Bio-pool, Umeå, Sweden and TAT: TAT (SRL); SRL, Tokyo, Japan). The AT-III activity, PLG and ␣2-PI were determined by the Hitachi auto-analyzer 7070 with commercial kits (AT-III: Testzyme S AT-III, PLG: Testzyme S PLG and ␣2-PI: Testzyme S APL; Daiichikagaku, Tokyo, Japan). Fbg were assessed with a coagulometer and commercial kits (Fibrinoquik; Organonteknika, Durham, NC, USA).
Measurement of serum P-III-P
Serum samples for measurement of P-III-P were collected at the same time as plasma samples for assays of coagulation-fibrinolysis parameters and stored at −80°C until analysis. P-III-P was measured by radioimmunoassay (Riagnost P III Pc.t.; CIS Bio International, Saclay, France).
Statistical analysis
The repeated measures analysis of variance (ANOVA) was used to analyze differences in each parameter between patients with and without VOD. Statistical significance between the values of each parameter at different times in patients with and without VOD was determined by the Student's t-test. P Ͻ 0.05 was considered significant. Multivariate analysis of the established risk factors for VOD and P-III-P before preparative chemotherapy was carried out with the multiple logistic regression analysis.
Results
Patient characteristics
Of the 44 patients, five developed VOD (ALL 3, CML 1, RAEB in T:1) ( Table 1 ). All five patients with VOD received serologically HLA-matched allogeneic marrow grafts; three were unrelated and the other two were related. Three of the five patients underwent conditioning with Ara-C + CY + TBI and the rest with BU + CY + TLI. One of the five patients died of multiorgan failure (Table 2) . Two patients who received a second hematopoietic stem cell transplant did not develop VOD. The median onset of VOD was day 3 (range, 3-12 days). One patient (UPN 282) received recombinant tissue plasminogen activator (rt-PA) (6 × 10 6 U/day × 2days) on days 10 and 11. Four other patients did not receive any treatments which might affect later coagulation profile data.
In one patient (a 37-year-old male, CML in first chronic phase, first BMT from an unrelated donor), the serum bilirubin exceeded 2.0 mg/dl and the body weight became more than 102% of baseline on day 12. This patient could not be diagnosed as having VOD, because he was suffering from acute GVHD at the same time. Excluding this patient, statistical analysis was carried out on 43 patients.
Serum P-III-P in adults with or without VOD
In the two-way ANOVA with repeated measurements, there were significant differences between patients with and without VOD in P-III-P (P Ͻ 0.0001). Before preparative chemotherapy (P Ͻ 0.005) and on days 0 and 7 (P Ͻ 0.001), the levels of P-III-P were significantly higher in patients with VOD than without VOD (Figure 1 ).
Coagulation-fibrinolysis parameters
In the two-way ANOVA with repeated measurements, there were significant differences between patients with and without VOD in protein C (P Ͻ 0.0001), t-PA (P Ͻ 0.0001), PLG (P Ͻ 0.0001), AT-III (P Ͻ 0.0001), Fbg (P Ͻ 0.0001) and ␣2-PI (P = 0.0002) (Figures 1 and 2) . On day 0, the levels of t-PA were significantly higher in patients with VOD than without VOD (P Ͻ 0.05). On day 7, the levels of protein C were significantly lower in patients with VOD than without VOD (P Ͻ 0.01). On day 0, there were trends of differences (P = 0.0515) between patients with VOD and without VOD in the levels of protein C (Figure 1 ). = chronic myelogenous leukemia; CP 1 = first chronic phase; ALL = acute lymphoblastic leukemia; CR 1 = first complete remission; RAEB in T = refractory anemia with excess of blasts in transformation; Rel 1 = first relapse; DFS = disease-free survival.
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Univariate analysis of established risk factors for VOD and P-III-P
Univariate analysis of established risk factors for VOD (serum ALT, AST 3 and albumin 2 ) and P-III-P was carried out before preparative chemotherapy (Table 3) . P-III-P before preparative chemotherapy was the only significant risk factor.
Multivariate analysis of established risk factors for VOD and P-III-P
Multivariate analysis of established risk factors for VOD and P-III-P was done before preparative chemotherapy ( Table 4) . P-III-P before preparative chemotherapy was more influential on occurrence of VOD than was any other risk factor examined.
Discussion
Coagulation-fibrinolysis parameters and P-III-P in patients undergoing allogeneic HSCT have been studied. The numbers of patients in almost all previous reports have been small and conclusions inconsistent. Although Faioni et al 6 suggested that protein C levels before the start of conditioning would indicate patients at risk for developing VOD, many others have failed to demonstrate that pre-conditioning levels of various coagulation-fibrinolysis parameters can predict for the development of VOD in patients undergoing HSCT. However, decrease of natural anticoagulants and change of fibrinolytic activity following HSCT have been shown to be relevant to the occurrence of VOD in several reports. [10] [11] [12] [13] [14] [15] Specifically, protein C and AT-III decreased usually 0-14 days after marrow infusion in patients with VOD. 10, 12, 15 PAI-1 has been reported to identify VOD in patients with post-transplant hyperbilirubinemia.
14 Significant increase in P-III-P has been reported in patients with VOD after HSCT. 8, 9, 16, 17 In our study, we prospectively measured the level of coagulation-fibrinolysis markers and P-III-P in 44 consecutive patients undergoing allogeneic HSCT. Levels of P-III-P were significantly higher in patients with VOD than Changes in N-terminal propeptide for type III procollagen (P-III-P), protein C activity, tissue plasminogen activator (t-PA) and plasminogen activity (PLG) in patients with and without VOD after hematopietic stem cell transplantation. Each P-value in the repeated measures analysis of variance (ANOVA), was represented on the right side of a figure. By means of the two-way ANOVA with repeated measurements, there were significant differences between patients with and without VOD in P-III-P (P Ͻ 0.0001), protein C (P Ͻ 0.0001), t-PA (P Ͻ 0.0001), PLG (P Ͻ 0.0001). Before preparative chemotherapy (P Ͻ 0.005) and on days 0 and 7 (P Ͻ 0.001) , the levels of P-III-P were significantly higher in patients with VOD than without VOD. On day 0, the levels of t-PA were significantly higher in patients with VOD than without VOD (P Ͻ 0.05). On day 7, the levels of protein C were significantly lower in patients with VOD than without VOD (P Ͻ 0.01). On day 0, there were trends of differences (P = 0.0515) between patients with VOD and without VOD in the levels of protein C. By means of the two-way ANOVA with repeated measurements, there were significant differences between patients with and without VOD in AT-III (P Ͻ 0.0001), Fbg (P Ͻ 0.0001), ␣2-PI (P = 0.0002). Table 3 Univariate analysis of established risk factors for VOD and P-III-P
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Risk factors
Patients 4.14 ± 0.07 4.07 ± 0.06 0.658 P-III-P (pre)
1.18 ± 0.15 0.66 ± 0.05 0.002 (U/ml) s.e. = standard error; pre = before preparative chemotherapy; AST = serum aspartate aminotransferase; ALT = serum alanine aminotransferase; Alb = serum albumin.
Table 4
Multivariate analysis of established risk factors for VOD and P-III-P
Risk factors
Parameter estimate P value AST (pre) (IU/l) −0.059 0.481 ALT (pre) (IU/l) 0.013 0.734 Alb (pre) (g/dl) −1.318 0.507 P-III-P (pre) (U/ml) −2.911 0.054 pre = before preparative chemotherapy; AST = serum aspartate aminotransferase; ALT = serum alanine aminotransferase; Alb = serum albumin.
without VOD, even before preparative chemotherapy, as well as on days 0 and 7. These findings suggest that serum P-III-P levels before the start of conditioning may indicate patients at risk for developing VOD, and P-III-P levels on day 0 are an early predictive marker for the development of VOD. Although there were trends towards differences between patients with and without VOD in P-III-P levels before the start of conditioning in the paper of Heikinheimo et al, 9 it has not been reported that P-III-P levels were significantly higher in patients with VOD than without VOD before preparative chemotherapy. P-III-P has been found to be a sensitive marker for pulmonary and liver fibrosis. 18, 19 Therefore, it can be an early predictive marker for the development of VOD, because fibrous obliteration of terminal hepatic venules and small lobular veins is the pathologic hallmark of VOD. Patients who develop VOD may have fibrous change (due to prior chemotherapy etc) of the liver before conditioning. It has been reported that poor hepatic function reserve may be a risk factor for hepatic VOD. 20, 21 Our results might be relevant to this hypothesis, because fibrous change can result in poor functional reserve of the liver.
On day 0, levels of t-PA were significantly higher in patients with VOD than without VOD in this study. Catani et al 22 reported t-PA and PAI-1 levels to be elevated at the onset of VOD in two VOD patients. The occurrence of VOD may be closely related to hypercoagulability. Seeber et al 23 reported endothelial coagulation factors such as t-PA and PAI-1 to be released by activation and/or damage to endothelial cells following an increase in serum tissue necrosis factor ␣ (TNF-␣). Vanhinsbergh et al 24 found a significant increase in t-PA and PAI-1 following infusion of recombinant human TNF-␣. Salat et al 14 measured t-PA and PAI-1 in 32 patients undergoing BMT. The levels of PAI-1 were significantly higher in patients with VOD than without VOD on day 14. Although they did not mention the fact, levels of t-PA tended to be higher in patients with VOD than those without VOD on day 0. Although PAI-1 has been reported to be very useful in the differential diagnosis of hyperbilirubinemia after BMT, 14 t-PA may be an early predictive marker for the development of VOD.
On day 7, levels of protein C were significantly lower in patients with VOD than in those without VOD in this study. This finding is consistent with previous reports, 12, 15 and may simply have resulted from decreased hepatic synthesis associated with VOD, although changes in coagulation parameters may indicate that the natural anticoagulant has some pathogenetic role in the development of VOD. Regardless of whether decreased levels of protein C are a cause or result of VOD, they are likely to aggravate its clinical effects.
Univariate and multivariate analysis of established risk factors for VOD and P-III-P before preparative chemotherapy were undertaken. These results suggest P-III-P is an independent risk factor for VOD .
Our data suggest that P-III-P, t-PA and protein C are predictive markers for hepatic VOD after allogeneic hematopoietic stem cell transplantation in adults. Moreover, serum P-III-P levels before the start of conditioning might indicate patients at risk for developing VOD. Prophylactic administration of protein C in patients whose P-III-P levels are high before the start of conditioning or on day 0 of HSCT, should be investigated.
